Get the Stockscreener App
6.385
11.26%
-0.81
After Hours:
6.46
0.075
+1.17%
Precigen Inc stock is traded at $6.385, with a volume of 5.48M.
It is down -11.26% in the last 24 hours and down -14.12% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$7.195
Open:
$7.19
24h Volume:
5.48M
Relative Volume:
1.22
Market Cap:
$2.29B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-4.5614
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
-18.25%
1M Performance:
-14.12%
6M Performance:
+61.65%
1Y Performance:
+82.95%
1-Day Range:
$6.305
$7.22
1-Week Range:
$6.305
$7.87
52-Week Range:
$3.04
$8.98
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
6.385 | 2.29B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-26 | Initiated | B. Riley Securities | Buy |
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Zacks Investment Research
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Precigen Inc For: 25 September - Investing.com India
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com UK
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
A treatment platform could help speed future drugs, Precigen says - Stock Titan
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? - Yahoo Finance
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares - GuruFocus
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Nigeria
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Australia
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Canada
Precigen (PGEN) director sells 185K shares in one day - Stock Titan
Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy? - Yahoo Finance
Is Precigen (PGEN) Undervalued After Reaching Quarterly Profitability? - sahmcapital.com
Precigen Director Sold Shares Worth Over $1.3M - TradingView
Precigen director Jeffrey Kindler sells $1.38m in stock - Investing.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Precigen (PGEN) director plans 185,000-share 2026 sale - Stock Titan
Precigen director Nancy H. Agee buys $24,661 of PGEN stock - investing.com
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com South Africa
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com Nigeria
Precigen CCO Phil Tennant sells $593,745 in stock By Investing.com - Investing.com Nigeria
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com India
Precigen Insider Sold Shares Worth $375,000, According to a Recent SEC Filing - marketscreener.com
Precigen (PGEN) insider lines up another stock sale after four recent trades - Stock Titan
Precigen (NASDAQ: PGEN) officer to sell 79,166 shares in 2026 - Stock Titan
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Investing News Network
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - ACCESS Newswire
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - New Castle News
Precigen (PGEN) director adds 3,411 shares in open-market buy - Stock Titan
Precigen (PGEN) COO unloads 50K shares at $7.50 under plan - Stock Titan
Precigen Q2 Results: Profitability returns as PAPZIMEOS revenue doubles - scanx.trade
Precigen CCO Phil Tennant sells $593,745 in stock - Investing.com
Precigen COO Rutul Shah sells $375,000 in shares - Investing.com
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KINDLER JEFFREY B | Director |
Aug 26 '26 |
Sale |
7.44 |
185,000 |
1,376,400 |
17,100 |
| Jeffrey Kindler | Director |
Aug 26 '26 |
Proposed Sale |
7.42 |
185,000 |
1,372,700 |
0 |
| Tennant Phil | Chief Commercial Officer |
Aug 25 '26 |
Option Exercise |
1.61 |
79,166 |
127,457 |
221,158 |
| Tennant Phil | Chief Commercial Officer |
Aug 25 '26 |
Sale |
7.50 |
79,166 |
593,745 |
141,992 |
| Shah Rutul R | Officer |
Aug 25 '26 |
Proposed Sale |
7.50 |
15,342 |
115,065 |
0 |
| Shah Rutul R | Chief Operating Officer |
Aug 25 '26 |
Sale |
7.50 |
15,342 |
115,065 |
468,865 |
| Tennant Phil | Officer |
Aug 25 '26 |
Proposed Sale |
7.50 |
79,166 |
593,745 |
0 |
| Shah Rutul R | Chief Operating Officer |
Aug 25 '26 |
Option Exercise |
2.33 |
15,342 |
35,747 |
484,207 |
| AGEE NANCY H | Director |
Aug 21 '26 |
Buy |
7.23 |
3,411 |
24,662 |
309,187 |
| Shah Rutul R | Chief Operating Officer |
Aug 21 '26 |
Option Exercise |
2.33 |
34,658 |
80,753 |
499,670 |
0.84%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):